Page 94 - NobleCon20-Book-Project

Health Care
Date November 19, 2024 Health Care
52wk High $2.48
52wk Low $0.22 IN8bio, Inc. INAB $0.35
350 5th Avenue
New York, NY 10118

(USD - in millions) in8bio.com
Market Cap 15.7
Enterprise 17.2
Basic Shares Out. 46.79 COMPANY OVERVIEW
Float 25.92
Institutional Holdings 18.35% Detailed Analysis:Channelchek.com
Short Interest 1.00
Avg. 90-Day Volume 1.10
IN8bio is a clinical-stage biopharmaceutical company developing
gamma-delta T cell-based immunotherapies for cancer patients.
Gamma-delta T cells are a specialized population of T cells that
EPS Data possess unique properties, including the ability to differentiate between
healthy and diseased tissue. The company’s lead program, INB-100, is
2022 2023 2024 focused on AML evaluating haplo-matched allogenic gamma-delta T
CQ1 (0.33) (0.30) (0.20) cells given to patients following a hematopoietic stem cell transplant.
CQ2 (0.38) (0.27) (0.19) The company is also evaluating autologous DeltEx DRI gamma-delta T
cells, in combination with standard of care, for glioblastoma.
CQ3 (0.34) (0.23) (0.15)
CQ4 (0.31) (0.21) (0.09)
CY (1.36) (1.00) (0.58) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.18
ROE (ttm) -241.97
Debt-to-Total Cap. (mrq) 38.92
Fiscal Year End 31-Dec
350 5th AvenuNew York NY 10118

Key Executives
CEO: Ho, Tai-Wei
CFO: McCall, Patrick
COO: Rochlin, Kate
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures